VZV

QuidelOrtho Receives 510(K) Clearance for Savanna® Multiplex Molecular Platform and Savanna® HSV 1+2/VZV PCR Assay

Retrieved on: 
Wednesday, December 20, 2023

The clearance allows QuidelOrtho to market and sell the Savanna multiplex molecular platform and the Savanna HSV 1+2/VZV assay to laboratories performing moderate or high complexity diagnostic testing in the United States.

Key Points: 
  • The clearance allows QuidelOrtho to market and sell the Savanna multiplex molecular platform and the Savanna HSV 1+2/VZV assay to laboratories performing moderate or high complexity diagnostic testing in the United States.
  • “Our relentless pursuit of revolutionizing testing across the healthcare continuum has resulted in the achievement of another major milestone – the clearance of our Savanna platform and the Savanna HSV 1+2/VZV assay,” said Douglas Bryant, President and Chief Executive Officer of QuidelOrtho.
  • Savanna is a fully integrated, sample-to-result, automated in vitro diagnostic platform that performs real-time polymerization chain reaction (“PCR”) tests by using the Savanna instrument and Savanna assay cartridges.
  • The Savanna HSV 1+2/VZV test panel is intended to aid in the differential diagnosis of infections with these viruses.

EQS-News: Biotest AG: Biotest treats first shingles patient with Varitect® CP in VARIZOSTA study

Retrieved on: 
Tuesday, September 5, 2023

High medical need in severe cases of herpes zoster (shingles) and resulting severe chronic nerve pain.

Key Points: 
  • High medical need in severe cases of herpes zoster (shingles) and resulting severe chronic nerve pain.
  • Biotest AG today announces that the first patient has been documented in the prospective, multicentre observational study VARIZOSTA conducted by Biotest.
  • The study will evaluate the use of the herpes zoster virus-specific hyperimmunoglobulin Varitect® CP (VZV-IgG) in complex herpes zoster, particularly in patients with a high risk constellation for severe disease progression.
  • The non-interventional study, in which 120 patients treated with VZV-IgG and 40 control patients are included, is being conducted at about 15 centres in Germany.

North America Immunodiagnostic Market Report 2022: Technological Advancements in The Field of Immunodiagnostics to Shape Industry Moving Forward - ResearchAndMarkets.com

Retrieved on: 
Friday, November 11, 2022

The "North America Immunodiagnostic Market Forecast to 2028 - COVID-19 Impact and Regional Analysis - by Product, Clinical Indication and End User" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "North America Immunodiagnostic Market Forecast to 2028 - COVID-19 Impact and Regional Analysis - by Product, Clinical Indication and End User" report has been added to ResearchAndMarkets.com's offering.
  • The North America immunodiagnostic market is expected to reach US$ 15,040.40 million in 2028 from US$ 9,188.19 million in 2021.
  • The market growth is mainly attributed to factors such as the increasing prevalence of infectious diseases and the rising use of point-of-care immunodiagnostics.
  • Based on product, the immunodiagnostic market is segmented into enzyme-linked immunosorbent assays (ELISA), chemiluminescence immunoassays (CLIA), radioimmunoassays (RIA), and others.

EQS-News: This Company Is Looking For A Monkeypox Drug As City Investigates Deaths

Retrieved on: 
Friday, October 28, 2022

Tackling monkeypox head-on, NanoViricides Inc. (NYSE: NNVC) is launching a monkeypox initiative.

Key Points: 
  • Tackling monkeypox head-on, NanoViricides Inc. (NYSE: NNVC) is launching a monkeypox initiative.
  • NanoViricides believes it will be able to develop a drug in response to monkeypox in relatively quick order.
  • NanoViricides, Inc. (the "Company") (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for antiviral therapy.
  • The Company believes that since Remdesivir is already US FDA approved, our drug candidate encapsulating Remdesivir is likely to be an approvable drug, if safety is comparable.

EQS-News: NanoViricides Reports Its Novel Monkeypox Antiviral Could Reach Clinical Status Rapidly

Retrieved on: 
Monday, September 19, 2022

In response to that rapid spread, NanoViricides Inc. (NYSEAMERICAN: NNVC) wants to speed up the timeline on the development of its novel antiviral platform to treat the monkeypox virus.

Key Points: 
  • In response to that rapid spread, NanoViricides Inc. (NYSEAMERICAN: NNVC) wants to speed up the timeline on the development of its novel antiviral platform to treat the monkeypox virus.
  • Heres the companys plan for bringing its monkeypox drug development platform to clinical trials sooner.
  • Having already begun drug development of NV-387-T, its monkeypox drug candidate, NanoViricides reports that its optimistic it can speed up the process to move the antiviral into human clinical trials quickly.
  • NanoViricides, Inc. (the "Company") (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for antiviral therapy.

QIAGEN Launches Syndromic Test for QIAstat-Dx Device to Combat Global Monkeypox Health Emergency

Retrieved on: 
Monday, August 15, 2022

The new panel currently for research use only (RUO) comes in cartridge form to run on QIAGENs QIAstat-Dx automated syndromic testing devices.

Key Points: 
  • The new panel currently for research use only (RUO) comes in cartridge form to run on QIAGENs QIAstat-Dx automated syndromic testing devices.
  • Currently the worlds only syndromic test for the pathogen, the panel will prove to be crucial for detecting and then combatting the spread of monkeypox around the globe.
  • The panels RUO-status means it currently can only be used for the surveillance not screening or diagnosing of monkeypox cases.
  • QIAGEN teams around the world are working with healthcare authorities to support testing for the monkeypox virus outbreak.

DGAP-News: Monkeypox Is Popping Up In Places It Shouldn’t But NanoViricides Says It May Have A Solution

Retrieved on: 
Wednesday, August 10, 2022

However, most of the monkeypox virus particles exit due to cell lysis, and are infectious even though not fully mature; this mode is not affected by TPOXX.

Key Points: 
  • However, most of the monkeypox virus particles exit due to cell lysis, and are infectious even though not fully mature; this mode is not affected by TPOXX.
  • It had shown effectiveness in monkeys to increase survival upon monkeypox virus infection.
  • Thus there is a clear and immediate need for rapid new drug development against monkeypox virus and potential variants.
  • During the smallpox eradication program in the late 1960s, the vaccine used to prevent smallpox also helped curb monkeypox infections.

Global Herpes Zoster Treatment Market Report to 2030 - Players Include Bausch Health, Cipla and Camber Pharmaceuticals - ResearchAndMarkets.com

Retrieved on: 
Friday, June 17, 2022

The "Herpes Zoster Treatment Market by Treatment Type Route Administration and Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2021-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Herpes Zoster Treatment Market by Treatment Type Route Administration and Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2021-2030" report has been added to ResearchAndMarkets.com's offering.
  • The global herpes zoster treatment market was valued at $217.09 million in 2020, and is projected to reach $303.42 million by 2030, registering a CAGR of 3.4% from 2021 to 2030.
  • In addition, individuals with herpes zoster can infect another person who never had chicken pox, yet the individual will foster chicken pox and not herpes zoster.
  • This report provides an extensive analysis of the current and emerging market trends and dynamics in the global herpes zoster treatment market to identify the prevailing opportunities.

New Large-Scale Observational Study Shows COVID-19 Could Create Vulnerability to Shingles for People Age 50+

Retrieved on: 
Wednesday, April 6, 2022

In this retrospective cohort study, people aged 50 or older who contracted COVID-19 were 15% more likely to develop shingles compared to controls who were never diagnosed with COVID-19.

Key Points: 
  • In this retrospective cohort study, people aged 50 or older who contracted COVID-19 were 15% more likely to develop shingles compared to controls who were never diagnosed with COVID-19.
  • The study observed adults aged 50 years and older using claims data from two large US databases and matched persons with and without COVID-19 using various known shingles risk factors.
  • The study authors, as well as case report publications , suggest that COVID-19 could trigger shingles by disrupting immune cells, allowing VZV to reactivate.
  • Individuals with a first-time COVID-19 diagnosis were matched with controls according to age, sex, shingles risk factors and healthcare costs.

Pfizer and BioNTech Sign New Global Collaboration Agreement to Develop First mRNA-based Shingles Vaccine

Retrieved on: 
Wednesday, January 5, 2022

The collaboration builds on the companies success in developing the first approved and most widely used mRNA vaccine to help prevent COVID-19.

Key Points: 
  • The collaboration builds on the companies success in developing the first approved and most widely used mRNA vaccine to help prevent COVID-19.
  • This is the third collaboration between Pfizer and BioNTech in the infectious diseases field, following the influenza vaccine collaboration initiated in 2018 and the COVID-19 vaccine collaboration initiated in 2020.
  • Pfizer will have rights to commercialize the potential vaccine on a global basis, with the exception of Germany, Turkey and certain developing countries where BioNTech will have commercialization rights.
  • The collaboration aims to develop a new mRNA-based vaccine against shingles, leveraging the expertise and resources of both companies, said Ugur Sahin, M.D., CEO and Co-Founder of BioNTech.